Click for best price
Hemophilia A B Recombinant Factor Replacement Therapy Market Size, Share 2022
Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptoms include bleeding from any site of the body. Internal bleeding is fatal as internal bleeding inside the joint causes joint damage and inside the brain, causes brain damage and seizers. The disease is inherited in an X-linked recessive genetic pattern, therefore males are commonly affected with haemophilia while females are usually carriers of the disease. Haemophilia A is caused by the deficiency of clotting Factor VIII, whereas haemophilia B is caused by the deficiency of Factor IX. It is also known as Christmas disease. The disease management includes factor replacement therapy. Factor replacement therapy is the infusion of factor VIII and IX concentrates through injection to control bleeding. These factor concentrates come from two sources i.e. from human plasma or from genetically engineered cell line made by recombinant DNA technology.
This report contains market size and forecasts of Hemophilia A and B Recombinant Factor Replacement Therapy in Global, including the following market information:
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hemophilia A and B Recombinant Factor Replacement Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Haemophilia A Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hemophilia A and B Recombinant Factor Replacement Therapy include Pfizer, Novo Nordisk, Baxalta, Bayer, Biogen, CSL Behring, Emergent Biosolutions, Spark therapeutics and Uniqure. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hemophilia A and B Recombinant Factor Replacement Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Segment Percentages, by Type, 2021 (%)
Haemophilia A
Haemophilia B
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Ambulatory Surgical Centers
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hemophilia A and B Recombinant Factor Replacement Therapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hemophilia A and B Recombinant Factor Replacement Therapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Novo Nordisk
Baxalta
Bayer
Biogen
CSL Behring
Emergent Biosolutions
Spark therapeutics
Uniqure
| Report Attributes |
Report Details |
| Report Title |
Hemophilia A and B Recombinant Factor Replacement Therapy Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
69 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Hemophilia A and B Recombinant Factor Replacement Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Overall Market Size
2.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size: 2021 VS 2028
2.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Hemophilia A and B Recombinant Factor Replacement Therapy Players in Global Market
3.2 Top Global Hemophilia A and B Recombinant Factor Replacement Therapy Companies Ranked by Revenue
3.3 Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Companies
3.4 Top 3 and Top 5 Hemophilia A and B Recombinant Factor Replacement Therapy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Hemophilia A and B Recombinant Factor Replacement Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hemophilia A and B Recombinant Factor Replacement Therapy Players in Global Market
3.6.1 List of Global Tier 1 Hemophilia A and B Recombinant Factor Replacement Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Hemophilia A and B Recombinant Factor Replacement Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Markets, 2021 & 2028
4.1.2 Haemophilia A
4.1.3 Haemophilia B
4.2 By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue & Forecasts
4.2.1 By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2022
4.2.2 By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2023-2028
4.2.3 By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Ambulatory Surgical Centers
5.2 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue & Forecasts
5.2.1 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2022
5.2.2 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2023-2028
5.2.3 By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2021 & 2028
6.2 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue & Forecasts
6.2.1 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2022
6.2.2 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2023-2028
6.2.3 By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2028
6.3.2 US Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.3.3 Canada Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.3.4 Mexico Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2028
6.4.2 Germany Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.4.3 France Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.4.4 U.K. Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.4.5 Italy Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.4.6 Russia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.4.7 Nordic Countries Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.4.8 Benelux Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2028
6.5.2 China Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.5.3 Japan Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.5.4 South Korea Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.5.5 Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.5.6 India Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2028
6.6.2 Brazil Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.6.3 Argentina Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2028
6.7.2 Turkey Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.7.3 Israel Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.7.4 Saudi Arabia Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
6.7.5 UAE Hemophilia A and B Recombinant Factor Replacement Therapy Market Size, 2017-2028
7 Players Profiles
7.1 Pfizer
7.1.1 Pfizer Corporate Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
7.1.4 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)
7.1.5 Pfizer Key News
7.2 Novo Nordisk
7.2.1 Novo Nordisk Corporate Summary
7.2.2 Novo Nordisk Business Overview
7.2.3 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
7.2.4 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)
7.2.5 Novo Nordisk Key News
7.3 Baxalta
7.3.1 Baxalta Corporate Summary
7.3.2 Baxalta Business Overview
7.3.3 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
7.3.4 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)
7.3.5 Baxalta Key News
7.4 Bayer
7.4.1 Bayer Corporate Summary
7.4.2 Bayer Business Overview
7.4.3 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
7.4.4 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)
7.4.5 Bayer Key News
7.5 Biogen
7.5.1 Biogen Corporate Summary
7.5.2 Biogen Business Overview
7.5.3 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
7.5.4 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)
7.5.5 Biogen Key News
7.6 CSL Behring
7.6.1 CSL Behring Corporate Summary
7.6.2 CSL Behring Business Overview
7.6.3 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
7.6.4 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)
7.6.5 CSL Behring Key News
7.7 Emergent Biosolutions
7.7.1 Emergent Biosolutions Corporate Summary
7.7.2 Emergent Biosolutions Business Overview
7.7.3 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
7.7.4 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)
7.7.5 Emergent Biosolutions Key News
7.8 Spark therapeutics
7.8.1 Spark therapeutics Corporate Summary
7.8.2 Spark therapeutics Business Overview
7.8.3 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
7.8.4 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)
7.8.5 Spark therapeutics Key News
7.9 Uniqure
7.9.1 Uniqure Corporate Summary
7.9.2 Uniqure Business Overview
7.9.3 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Major Product Offerings
7.9.4 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global Market (2017-2022)
7.9.5 Uniqure Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Hemophilia A and B Recombinant Factor Replacement Therapy Market Opportunities & Trends in Global Market
Table 2. Hemophilia A and B Recombinant Factor Replacement Therapy Market Drivers in Global Market
Table 3. Hemophilia A and B Recombinant Factor Replacement Therapy Market Restraints in Global Market
Table 4. Key Players of Hemophilia A and B Recombinant Factor Replacement Therapy in Global Market
Table 5. Top Hemophilia A and B Recombinant Factor Replacement Therapy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Share by Companies, 2017-2022
Table 8. Global Companies Hemophilia A and B Recombinant Factor Replacement Therapy Product Type
Table 9. List of Global Tier 1 Hemophilia A and B Recombinant Factor Replacement Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hemophilia A and B Recombinant Factor Replacement Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings
Table 32. Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$, Mn), (2017-2022)
Table 33. Novo Nordisk Corporate Summary
Table 34. Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings
Table 35. Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$, Mn), (2017-2022)
Table 36. Baxalta Corporate Summary
Table 37. Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings
Table 38. Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$, Mn), (2017-2022)
Table 39. Bayer Corporate Summary
Table 40. Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings
Table 41. Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$, Mn), (2017-2022)
Table 42. Biogen Corporate Summary
Table 43. Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings
Table 44. Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$, Mn), (2017-2022)
Table 45. CSL Behring Corporate Summary
Table 46. CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings
Table 47. CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$, Mn), (2017-2022)
Table 48. Emergent Biosolutions Corporate Summary
Table 49. Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings
Table 50. Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$, Mn), (2017-2022)
Table 51. Spark therapeutics Corporate Summary
Table 52. Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings
Table 53. Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$, Mn), (2017-2022)
Table 54. Uniqure Corporate Summary
Table 55. Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Product Offerings
Table 56. Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Hemophilia A and B Recombinant Factor Replacement Therapy Segment by Type in 2021
Figure 2. Hemophilia A and B Recombinant Factor Replacement Therapy Segment by Application in 2021
Figure 3. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Hemophilia A and B Recombinant Factor Replacement Therapy Revenue in 2021
Figure 8. By Type - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028
Figure 9. By Application - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028
Figure 10. By Region - Global Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028
Figure 11. By Country - North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028
Figure 12. US Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028
Figure 16. Germany Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 17. France Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028
Figure 24. China Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 28. India Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028
Figure 30. Brazil Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Market Share, 2017-2028
Figure 33. Turkey Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Hemophilia A and B Recombinant Factor Replacement Therapy Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
